Kisqali on PBS, very few will get it.
those of us who were waiting to get Ibrance or Kisqali on PBS we will not get either. Only newly the diagnosed who have NOT had an Aromatose drug. ( there would be very few of them ) BCNA failed t...
Forum Discussion
1 in 8 women in Australia gets breast cancer.
Of those diagnosed with breast cancer 20-30% will have a recurrence during their life span.
For those living with Metastatic Breast Cancer there is no cure.
Metastatic Breast Cancer women will die of their disease. Two thirds of these women will die of their disease within 5 years.
CDK 4/6 drugs offer women with HR breast cancer the opportunity to at the very least delay the onset of chemotherapy drugs. Palbociclib is the most known and certainly the drug on which we have the most data.
It was approved by the FDA in February 2015 by accelerated approval.
Canada and the European Union followed suite.
More than 3 years later this drug still NOT available in Australia on PBS.
Ribociclib has potential cardiac side effects that have not been the reported with Palbociclib.
The choice over which drug came down to money - the cheaper of the CDK4/6 has been granted PBS approval. Furthermore it is limited to women who have not been on AI - so what about all the postmenopausal women on AIs who develop metastasis? BC peak incidence is mid 50s through 60s. It is also not on PBS for men who have Metastatic breast cancer.
And yes, while they are compassionate programs - these women are going through enough not to be put through one more loop, one more jump, one more reminder of how vulnerable they are.
I agree that BCNA has not been entirely open about the ongoing fight and the political scene behind trying to bring CDK inhibitors to Australian women who are dying from Mestatstic Breast Cancer.
Of those diagnosed with breast cancer 20-30% will have a recurrence during their life span.
For those living with Metastatic Breast Cancer there is no cure.
Metastatic Breast Cancer women will die of their disease. Two thirds of these women will die of their disease within 5 years.
CDK 4/6 drugs offer women with HR breast cancer the opportunity to at the very least delay the onset of chemotherapy drugs. Palbociclib is the most known and certainly the drug on which we have the most data.
It was approved by the FDA in February 2015 by accelerated approval.
Canada and the European Union followed suite.
More than 3 years later this drug still NOT available in Australia on PBS.
Ribociclib has potential cardiac side effects that have not been the reported with Palbociclib.
The choice over which drug came down to money - the cheaper of the CDK4/6 has been granted PBS approval. Furthermore it is limited to women who have not been on AI - so what about all the postmenopausal women on AIs who develop metastasis? BC peak incidence is mid 50s through 60s. It is also not on PBS for men who have Metastatic breast cancer.
And yes, while they are compassionate programs - these women are going through enough not to be put through one more loop, one more jump, one more reminder of how vulnerable they are.
I agree that BCNA has not been entirely open about the ongoing fight and the political scene behind trying to bring CDK inhibitors to Australian women who are dying from Mestatstic Breast Cancer.